ESTRELLA IMMUNOPHARMA, INC. Increase (Decrease) in Income Taxes Payable
ESTRELLA IMMUNOPHARMA, INC. (ESLA) reported Increase (Decrease) in Income Taxes Payable of -$50 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-18.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable · last filed 2026-08-13
- ESTRELLA IMMUNOPHARMA, INC. increase (decrease) in income taxes payable for the quarter ending 2025-12-31 was $0.00.
- ESTRELLA IMMUNOPHARMA, INC. increase (decrease) in income taxes payable for the quarter ending 2025-09-30 was $0.00.
- ESTRELLA IMMUNOPHARMA, INC. increase (decrease) in income taxes payable for the quarter ending 2024-06-30 was -$200.00.
- ESTRELLA IMMUNOPHARMA, INC. increase (decrease) in income taxes payable for the quarter ending 2024-03-31 was $0.00, a 100.00% decline year-over-year.
- ESTRELLA IMMUNOPHARMA, INC. increase (decrease) in income taxes payable for fiscal 2025 was -$50.00.
- ESTRELLA IMMUNOPHARMA, INC. increase (decrease) in income taxes payable for fiscal 2024 was -$138.00, a 104.31% decline from fiscal 2023.
- ESTRELLA IMMUNOPHARMA, INC. increase (decrease) in income taxes payable for fiscal 2023 was $3.20K.
- ESTRELLA IMMUNOPHARMA, INC. increase (decrease) in income taxes payable for fiscal 2022 was $51.18K.
| Period end | Increase (Decrease) in Income Taxes Payable 3 month | Increase (Decrease) in Income Taxes Payable 6 month | Increase (Decrease) in Income Taxes Payable 9 month | Increase (Decrease) in Income Taxes Payable 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $0.00 derived: sum of 2 quarters · filed 2026-03-18 | -$50.00 10-K · filed 2026-03-18 | |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$50.00 10-Q · filed 2025-11-12 | ||
| 2025-06-30 | -$50.00 10-Q · filed 2026-08-13 | |||
| 2024-12-31 | -$40.69K 10-K · filed 2026-03-18 | |||
| 2024-06-30 | -$200.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-09-27 | -$200.00 derived: sum of 2 quarters · filed 2024-09-27 | $474.00 derived: sum of 3 quarters · filed 2024-09-27 | -$138.00 10-K · filed 2024-09-27 |
| 2024-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-05-15 | $674.00 derived: sum of 2 quarters · filed 2024-05-15 | $62.00 10-Q · filed 2024-05-15 | -$30.63K derived: sum of 4 quarters · filed 2024-05-15 |
| 2023-12-31 | $674.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-02-14 | $62.00 10-Q · filed 2024-02-14 | -$30.63K derived: sum of 3 quarters · filed 2024-02-14 | $10.53K derived: sum of 4 quarters · filed 2024-02-14 |
| 2023-09-30 | -$612.00 10-Q · filed 2023-11-20 | -$31.31K derived: sum of 2 quarters · filed 2023-11-20 | $9.86K derived: sum of 3 quarters · filed 2023-11-20 | $10.66K derived: sum of 4 quarters · filed 2024-02-14 |
| 2023-06-30 | -$30.70K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-01 | $10.47K 10-Q · filed 2023-08-01 | $11.27K derived: sum of 3 quarters · filed 2024-02-14 | $3.20K 10-K · filed 2024-09-27 |
| 2023-03-31 | $41.16K 10-Q · filed 2023-05-18 | $41.96K derived: sum of 2 quarters · filed 2024-02-14 | $2.40K 10-Q · filed 2024-05-15 | |
| 2022-12-31 | $800.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-02-14 | $1.60K 10-Q · filed 2024-02-14 | $51.18K 10-K · filed 2023-03-14 | |
| 2022-09-30 | $800.00 10-Q · filed 2023-11-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |